Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

To be considered for this study, you would need to have either Type B3 Thymoma or Thymic Carcinoma that has returned or spread, and can't be treated with surgery or other radical methods meant to cure it. You must have already had at least one round of chemotherapy for your advanced cancer, using a 'platinum-based' drug. Even if you had platinum-based chemotherapy before surgery or radiotherapy, you might still be eligible if it was less than six months ago and your cancer has progressed.

Your cancer must show signs of getting worse (progressing) during or after your previous chemotherapy, and doctors must be able to measure it on scans. You also need to be at least 18 years old and generally well enough to take part. This means your body needs to be able to handle the treatment, so doctors will check your blood tests to make sure your liver, kidneys, and blood cells are working well enough.

The research team will also need a sample of your tumour tissue, either from a past biopsy or surgery, to check for certain markers. This helps them understand more about your cancer and how the treatment might work, but your eligibility won't depend on the results of this test.

If you join the NIVOTHYM study, you will receive the study drug, nivolumab. You will have regular appointments for check-ups, blood tests, and scans (like CT or MRI scans of your chest and tummy) to see how you are responding to the treatment and to monitor your health. Sometimes, brain scans might also be needed. The length of time you will be on the treatment can vary, but generally, participants continue the treatment as long as it is benefiting them and they are not experiencing severe side effects. After stopping the treatment, there will likely be a follow-up period to continue monitoring your health and any long-term effects.